FLT3 and acute myeloid leukemia: In a phase III trial (QuANTUM-R study, n = 367), quizartinib showed a survival benefit versus (vs.)salvage chemotherapy (median OS of 6.2 months vs. 4.7 months; HR 0.76; 95% CI, 0.58–0.98; p = 0.02), with a manageable safety profile in R/R FLT3-ITD-positive AML patients [31].